Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Small molecules that promote neurogenesis in vitro.

Rishton GM.

Recent Pat CNS Drug Discov. 2008 Nov;3(3):200-8. Review.

PMID:
18991809
2.

Natural products as a robust source of new drugs and drug leads: past successes and present day issues.

Rishton GM.

Am J Cardiol. 2008 May 22;101(10A):43D-49D. doi: 10.1016/j.amjcard.2008.02.007. Review.

PMID:
18474274
3.

Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening.

Rishton GM.

Curr Opin Chem Biol. 2008 Jun;12(3):340-51. doi: 10.1016/j.cbpa.2008.02.008. Epub 2008 Mar 25. Review.

PMID:
18328272
4.

Aggregator compounds confound amyloid fibrillization assay.

Rishton GM.

Nat Chem Biol. 2008 Mar;4(3):159-60. doi: 10.1038/nchembio0308-159. No abstract available.

PMID:
18277973
6.
7.

Nonleadlikeness and leadlikeness in biochemical screening.

Rishton GM.

Drug Discov Today. 2003 Jan 15;8(2):86-96. Review.

PMID:
12565011
8.

Fenchylamine sulfonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease.

Rishton GM, Retz DM, Tempest PA, Novotny J, Kahn S, Treanor JJ, Lile JD, Citron M.

J Med Chem. 2000 Jun 15;43(12):2297-9. No abstract available.

PMID:
10882355
9.

Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard.

Poon B, Jowett JB, Stewart SA, Armstrong RW, Rishton GM, Chen IS.

J Virol. 1997 May;71(5):3961-71.

Supplemental Content

Loading ...
Support Center